

**Diaceutics PLC
("Diaceutics" or the "Group")**

Belfast investor presentation

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will hold a presentation for investors on Monday, 6 April 2020 in Belfast City. The presentation will be given jointly by Diaceutics and Fusion Antibodies plc, the specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.

On behalf of Diaceutics, Peter Keeling CEO, and Philip White, CFO, will give a Company update and overview. The event will take place at a venue in central Belfast and will commence with registration at 5.00pm for a 5.15pm start, followed by drinks and networking.

The format of the afternoon will be as follows:

5pm: arrival and registration

5.15pm: Welcome address

5.20pm - 5.50pm: Diaceutics presentation

5.50pm - 6.05pm: Q&A

6.10pm - 6.40pm: Fusion Antibodies presentation

6.40pm - 6.55pm: Q&A

7pm: Canapes, drinks and networking

8pm: Close

If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email diaceutics@walbrookpr.com.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer

Philip White, Chief Financial Officer

www.diaceutics.com

Via Walbrook PR

Walbrook PR

Anna Dunphy

Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Mob: +44 (0)7876 741 001

Mob: +44 (0)7980 541 893

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies.

The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects.

The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

www.diaceutics.com

NRASFWFFLESSELE